

Bifivir®

Synbiotic product • Immune defences

A valuable support to strengthen the immune defences and optimize their protective functions



Lactobacillus plantarum LP01 (LMG P-21021)
Lactobacillus plantarum LP02 (LMG P-21020)
Lactobacillus rhamnosus LR04 (DSM 16605)
Lactobacillus rhamnosus LR05 (DSM 19739)
Bifidobacterium lactis BS01 (LMG P-21384)

Immuno defence

The microbiota plays a fundamental role on the induction, training and function of the host immune system. When operating optimally, the alliance between the immune system and the microbiota interweaves the innate and adaptive arms of immunity in a dialogue that selects, calibrates and terminates responses in the most appropriate way.

Functionality

Bifivir® is synbiotic product able to induce a correct immune response of the lymphoid tissue associated with the enteric mucosa (GALT – Gut Associated Lymphoid Tissue) where 40% of the immunocompetent body cells can be found.

Bifivir® has shown to significantly reduce occurrence, severity and duration of the respiratory tract infections in different clinical trials. This product offers a cost-effective protection against the flu and other seasonal infections.

How to use

One sachet a day for 3 months, dissolved in a glass of water at room temperature, preferably in the morning before breakfast.



Powder in sachet



Probiotics like nobody else



Probiotal S.p.A. Via E. Mattei, 3, 28100 Novara (NO), Italy - T: +39 0321 46 59 33
F: +39 0321 49 26 93 - email: support@probiotal.com - www.probiotal.com

Bifivir®

Synbiotic product • Immune defences

A valuable support to strengthen the immune defences and optimize their protective functions

Lactobacillus plantarum LP01 (LMG P-21021)
Lactobacillus plantarum LP02 (LMG P-21020)
Lactobacillus rhamnosus LR04 (DSM 16605)
Lactobacillus rhamnosus LR05 (DSM 19739)
Bifidobacterium lactis BS01 (LMG P-21384)

SCIENTIFIC REFERENCES

Human clinical trials

1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.

2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.






Fig. 1 This study (1) demonstrates the ability of synbiotic Bifivir® to reduce the incidence, severity, and average length of total ARI episodes, which normally affect a large proportion of the population during the cold season.

In these figures are shown analysis of data regarding the number of episodes, severity, and duration of respiratory system diseases, occurred over the 90 days of treatment, in the Bifivir group vs Placebo (1).

In vitro studies

a) Mogna L et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization A New Approach. J Clin Gastroenterol 2018;52:S57-S61.

b) Deidda F, Graziano T, Amoruso A, De Prisco A, Marco P, De Prisco A (2020) How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. 8:216. DOI: 10.35248/2329-8901.20.8.216

PLUS POINTS:

- Demonstrated clinically to significantly reduce the prevalence, severity and duration of respiratory diseases including influenza-like illnesses
- Allergen free product (patented technology)
- Natural product without side effects
- Patented product

SAFETY & QUALITY

- ✓ Strains with Qualified Presumption of Safety status (QPS list from European Food Safety Agency)
- ✓ No adverse effects in clinical studies
- ✓ Produced according to the highest quality standards:
 - ✓ GMP
 - ✓ ISO 14001
 - ✓ ISO 9001
 - ✓ ISO 22000

